Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD.

Dev Cell. 2002 Sep;3(3):411-23.

2.

Dual role of Ang2 in postnatal angiogenesis and lymphangiogenesis.

Veikkola T, Alitalo K.

Dev Cell. 2002 Sep;3(3):302-4.

3.

Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation.

Gale NW, Thurston G, Davis S, Wiegand SJ, Holash J, Rudge JS, Yancopoulos GD.

Cold Spring Harb Symp Quant Biol. 2002;67:267-73. No abstract available.

PMID:
12858549
4.

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.

Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD.

Cell. 1996 Dec 27;87(7):1171-80.

5.

Selective functions of angiopoietins and vascular endothelial growth factor on blood vessels: the concept of "vascular domain".

Sato TN, Loughna S, Davis EC, Visconti RP, Richardson CD.

Cold Spring Harb Symp Quant Biol. 2002;67:171-80. No abstract available.

PMID:
12858538
6.

Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization.

Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM.

Circ Res. 1998 Aug 10;83(3):233-40.

7.

Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.

Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T.

Circ Res. 2001 Jan 19;88(1):22-9. Retraction in: Circ Res. 2013 Jun 7;112(12):e180.

8.

The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development.

Ward NL, Dumont DJ.

Semin Cell Dev Biol. 2002 Feb;13(1):19-27. Review.

PMID:
11969368
9.

Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.

Stratmann A, Acker T, Burger AM, Amann K, Risau W, Plate KH.

Int J Cancer. 2001 Feb 1;91(3):273-82.

10.

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.

Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V.

Blood. 2003 Jul 15;102(2):638-45. Epub 2003 Mar 20.

11.

Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization.

Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, Yancopoulos G, Campochiaro PA.

J Cell Physiol. 2000 Sep;184(3):275-84. Review.

PMID:
10911358
12.

Angiopoietin-1 induces sprouting angiogenesis in vitro.

Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W.

Curr Biol. 1998 Apr 23;8(9):529-32.

13.

Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice.

Dellinger M, Hunter R, Bernas M, Gale N, Yancopoulos G, Erickson R, Witte M.

Dev Biol. 2008 Jul 15;319(2):309-20. doi: 10.1016/j.ydbio.2008.04.024. Epub 2008 Apr 27.

14.

[Angiogenic inducers and inhibitors].

Shukunami C, Hiraki Y.

Tanpakushitsu Kakusan Koso. 2000 Sep;45(13 Suppl):2131-8. Review. Japanese. No abstract available.

PMID:
11021214
15.

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.

Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, Pierotti MA, Bongarzone I.

Am J Pathol. 1999 Dec;155(6):1967-76.

16.

Getting Tie(2)d up in angiogenesis.

Ramsauer M, D'Amore PA.

J Clin Invest. 2002 Dec;110(11):1615-7. No abstract available.

17.

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD.

Science. 1997 Jul 4;277(5322):55-60.

18.

Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling.

Currie MJ, Gunningham SP, Han C, Scott PA, Robinson BA, Harris AL, Fox SB.

Clin Cancer Res. 2001 Apr;7(4):918-27.

19.

Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.

Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Ylä-Herttuala S, Alitalo K.

FASEB J. 2002 Jul;16(9):1041-9.

PMID:
12087065
20.

Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization.

Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M, Honda Y.

Invest Ophthalmol Vis Sci. 2003 Jan;44(1):393-402.

PMID:
12506101

Supplemental Content

Support Center